Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age

References

• Creanga AA, Berg CJ, Syverson C, et al. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015;125(1):5–12. doi:10.1097/AOG.000000000000056425560097
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists (2015) Green-top Guideline No. 37b. Thromboembolic disease in pregnancy and the puerperium: acute management. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/.  Accessed March 1, 2019.
   Google Scholar
• Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variant in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased in venous thrombosis. Blood. 1996;88:3698–3703.8916933
   PubMed Web of Science ®Google Scholar
• Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 casecontrol studies including 2310 cases and 3204 controls. Study group for pooledanalysis in venous thromboembolism. Thromb Haemost. 2001;86(3):809–816.11583312
   PubMed Web of Science ®Google Scholar
• Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3ʹ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28(4):389–392. doi:10.1038/ng57811443298
   PubMed Web of Science ®Google Scholar
• Magnusson S.The Enzymes. 3rd edition Vol. 3 New York: Academic Press; 1971:277–321.
   Google Scholar
• Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5(Suppl 1):95–101. doi:10.1111/j.1538-7836.2007.02500.x17635715
   PubMed Web of Science ®Google Scholar
• Spector EB, Grody WW, Matteson CJ, et al. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G > A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med. 2005;7(6):444–453. doi: 10.109701.GIM.0000172641.57755.3A16024978
   PubMed Web of Science ®Google Scholar
• Dziadosz M, Baxi LV. Global prevalence of prothrombin gene mutation G20210A and implications in women’s health: a systematic review. Blood Coagul Fibrinolysis. 2016;27(5):481–489. doi:10.1097/MBC.000000000000056227058219
   PubMed Web of Science ®Google Scholar
• Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001;109(4):369–384. doi:10.1007/s00439010059311702218
   PubMed Web of Science ®Google Scholar
• Klein L, Bhardwaj V, Gebara B. Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype. J Perinatol. 2004;24:797–799. doi:10.1038/sj.jp.721118715558004
   PubMedGoogle Scholar
• Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost. 2007;5:98–101. doi:10.1111/j.1538-7836.2006.02291.x17067362
   PubMed Web of Science ®Google Scholar
• Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost. 2010;8(11):2443–2449. doi:10.1111/j.1538-7836.2010.04038.x20735725
   PubMed Web of Science ®Google Scholar
• Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International consensus statement. Int Angiol. 2013;32(2):111–260.24402349
   PubMed Web of Science ®Google Scholar
• Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164:1932–1937. doi:10.1001/archinte.164.17.193215451770
   PubMedGoogle Scholar
• Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301:2472–2485. doi:10.1001/jama.2009.85319531787
   PubMed Web of Science ®Google Scholar
• Williamson MA, Snyder LM, Wallach JB. Wallach’s Interpretation of Diagnostic Tests. 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011.
   Google Scholar
• Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527–1535. doi:10.1056/NEJM20010517344200711357157
   PubMed Web of Science ®Google Scholar
• Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164(18):1965–1976. doi:10.1001/archinte.164.18.196515477430
   PubMedGoogle Scholar
• Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) Study. Thromb Haemost. 2005;94(1):17–25. doi:10.1160/TH04-11-075916113779
   PubMed Web of Science ®Google Scholar
• Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–647. doi:10.1007/s10654-013-9825-823900608
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996;348:1027. doi:10.1016/S0140-6736(96)24041-3
   Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348(9033):983–987. doi:10.1016/S0140-6736(96)07308-48855854
   PubMed Web of Science ®Google Scholar
• Varga EA, Moll S. Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation. 2004;110(3):e15–8. doi:10.1161/01.CIR.0000135582.53444.8715262854
   PubMed Web of Science ®Google Scholar
• Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342(6):374–380. doi:10.1056/NEJM20000210342060210666427
   PubMed Web of Science ®Google Scholar
• Martinelli I, De Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002;87(5):791–795.12038778
   PubMed Web of Science ®Google Scholar
• Hertzberg MS. Genetic testing for thrombophilia mutations. Semin Thromb Hemost. 2005;31:33–38. doi:10.1055/s-2005-86380315706473
   PubMed Web of Science ®Google Scholar
• Momot AP, Nikolaeva MG, Elykomov VA, Momot KA. The role of APC-resistance for predicting venous thrombosis and pregnancy complicationsin carriers of factor V Leiden (1691) G/A mutation In: Pregnancy and Birth Outcomes. Intech Open; 2018:33–57. doi:10.5772/intechopen.72210
   Google Scholar
• Momot AP, Nikolaeva MG, Zainulina MS. The main causes of thrombotic events in carriage of Leiden mutation in women of reproductive age. J Hematol Thrombo Dis. 2018;6:296. doi:10.4172/2329-8790.1000296
   Google Scholar
• National Institute for Health and Clinical Excellence. Venous Thromboembolism: Reducing the Risk. Reducing the Risk of Venous Thromboembolism (deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital. NICE Clinical Guideline 92. London: NICE; 2010.
   Google Scholar
• Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90(5):1747–1750. http://www.bloodjournal.org/content/90/5/1747.long?sso-checked=true.9292507
   PubMed Web of Science ®Google Scholar
• Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease [review]. Thromb Haemost. 2001;85:584–595. doi:10.1055/s-0037-161563811341490
   PubMed Web of Science ®Google Scholar
• Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61(11):1652–1661. doi:10.1001/archneur.61.11.165215534175
   PubMedGoogle Scholar
• Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One. 2010;5(2):e9136. doi:10.1371/journal.pone.000913620161734
   PubMed Web of Science ®Google Scholar
• Korchagin VI, Mironov KO, Dribnokhodova OP, et al. The role of genetic factors in the development of individual predisposition to ischemic stroke. Hum Physiol. 2017;43(8):886–897. doi:10.1134/S0362119717080047
   Google Scholar
• Rallidis LS, Gialeraki A, Tsirebolos G, Tsalavoutas S, Rallidi M, Iliodromitis E. Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction. J Thromb Thrombolysis. 2017;44(2):267–273. doi:10.1007/s11239-017-1520-228647870
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49–52. doi:10.1001/archinte.160.1.4910632304
   PubMedGoogle Scholar
• Medical eligibility criteria for contraceptive use – 3rd ed. World Health Organization; 2004 ISNB 92 4 156266 8 (NLM classification: WP 630) Available from: http://bono-esse.ru/blizzard/Gyn/Contracep/MEC-merged_2004.pdf. Accessed March 1, 2019.
   Google Scholar
• Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143:321–335. doi:10.1111/j.1365-2141.2008.07339.x18710381
   PubMed Web of Science ®Google Scholar
• Stirllng Y, Woolf I, North WRS, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost. 1984;52:176–182.6084322
   PubMed Web of Science ®Google Scholar
• Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2010;24:339–352. doi:10.1016/j.bpobgyn.2009.11.01020097136
   PubMed Web of Science ®Google Scholar
• Momot AP, Semenova NA, Belozerov DE, Trukhina DA, Kudinova IY. The dynamics of the hemostatic parameters in physiological pregnancy and after delivery. J Hematol Blood Transfus Disord. 2016;3:005. doi:10.18411/d-2016-058
   Google Scholar
• The Oral Contraceptive and Hemostasis Study Group. The effects of seven monphasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomised multicenter study. Contraception. 2003;67:173–185. doi:10.1016/S0010-7824(02)00476-612618251
   PubMed Web of Science ®Google Scholar
• Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost. 2005;3:2497–2505. doi:10.1111/j.1538-7836.2005.01584.x16241948
   PubMed Web of Science ®Google Scholar
• Aldrighi JM, De Campos LS, Eluf Gebara OC, Petta CA, Bahamondes L. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters. Gynecol Endocrinol. 2006;22(1):1–4. doi:10.1080/09513590500430328
   PubMed Web of Science ®Google Scholar